retatrutide what is retatrutide clinical trials Let's talk about a new weight loss medication: retrarutide. a triple hormone receptor agonist that suppresses appetite; it also boosts metabolism and increases fat burning, making it one of the Retatrutide UK: 2026 Clinical Trial

These events were generally mild to moderate in severity and included: Nausea often accompanying changes in bowel habits, particularly after dose escalation Diarrhoea loose or watery stools, sometimes with urgency Vomiting less common but reported, especially at higher doses Constipation occurring in some individuals, reflecting the variable effect on gut motility Abdominal discomfort or bloating a sensation of fullness or cramping Flatulence increased wind, which can accompany altered digestion Gastrointestinal adverse events were the most common reason for discontinuation in the Phase 2 trial, occurring in approximately 510% of participants depending on dose group

Unlike some weight loss medications that require daily administration or strict timing around meals, semaglutide is injected just once a week

Consider this, back in 2024, Novo Nordisk, maker of Ozempic, had a market cap larger than the entire economy of Denmark, the company's home country

Most people experience something, but that doesn't mean most people have a bad experience

Read our full reviews here: Hims GLP-1 Clinic Review & Hers GLP-1 Clinic Review 4